Focus on Faculty With Markus Gutsche, MD, PhD
Markus Gutsche, MD, PhD, is an assistant professor of medicine and director of the Interstitial Lung Disease (ILD) Program at UC and within UC Health. Gutsche received his medical degree from the Albert Ludwig University of Freiburg in Germany as well as completed his residency at the Upstate University Hospital/SUNY Upstate Medical University in New York and a pulmonary and critical care fellowship at Stanford Medical Center in California.
What brought you to UC?
"During my training in pulmonary and critical care medicine at Stanford, I developed an interest in Interstitial Lung Diseases and underwent further subspecialty training within this field. The University of Cincinnati is well known for its expert work both in the clinical practice as well as cutting-edge research in rare lung diseases and ILD. I felt both inspired and honored by the prospect of helping to expand and further develop a comprehensive ILD program at UC and UC Health for patients with this challenging disorder who live in the Tristate area.
What is Interstitial Lung Disease?
"Interstitial Lung Disease comprises a large group of lung disorders most of which lead to progressive pulmonary fibrosis, or scarring of the lung tissue. The causes of interstitial lung disease can range from inhalation of hazardous material, like asbestos or certain dusts, to autoimmune diseases such as rheumatoid arthritis. However, often the cause remains unknown. Once lung scarring has occurred it is usually irreversible. While some patients may be candidates for lung transplantation some may actually benefit from early intervention and specific therapies to halt further progression to irreversible lung scarring.
Why did you decide to study or specialize in this disease? Please explain your specific ILD research focus, if applicable.
"The care of patients with ILD requires a very systematic approach including a comprehensive history and physical examination with particular attention to detail as well as collaboration with other specialtiesradiologists, pathologists, rheumatologists in a multidisciplinary approach. I have a vested interest in spending sufficient time with my patients to illuminate the cause of their ILD and explore appropriate treatment options. Because so many of the interstitial lung disorders are poorly understood, there also exists a great need for further research in this area to improve the overall care of patients afflicted by ILD.
What are your plans for the ILD program at UCboth clinically and scientifically?
"I strive to offer my patients the most comprehensive ILD care program within the Greater Cincinnati and Tristate area. We also plan to open an ILD clinic for our veterans at the (Cincinnati) VA. Over time, via systematic observation and data collection through our clinical work and by collaborating with scientists at UC, I am hopeful that we will make steady progress in understanding this group of challenging disorders and improve the overall management of our ILD population in this area.
Tags
Related Stories
Make Hoxworth Blood Center’s special holiday events part of your family celebrations this December
December 12, 2025
This December, Hoxworth Blood Center, University of Cincinnati, is inviting families across Greater Cincinnati to add something truly meaningful to their holiday traditions: giving the gift of life. With festive community events, beloved local partners and special thank-you gifts for donors, Hoxworth is making it easier, and more heartwarming than ever, to roll up your sleeves and help save lives close to home.
Ohio nurses weigh in on proposed federal loan rule
December 12, 2025
Spectrum News journalist Javari Burnett spoke with UC Dean Alicia Ribar and UC nursing students Megan Romero and Nevaeh Haskins about proposed new federal student loan rules. Romero and Haskins, both seniors, were filmed in the College of Nursing’s Simulation Lab.
New combination treatment improves multiple myeloma outcomes
December 11, 2025
The University of Cincinnati Cancer Center's Ed Faber, DO, provided commentary to Medscape on the COBRA study that found the combination of carfilzomib combined with lenalidomide and dexamethasone (KRd) shows significantly greater efficacy than the previous standard of care.